Source: OptiScan Imaging
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • OptiScan Imaging (OIL) has changed its distribution arrangements
  • The company has entered into an agreement with Advanced Microscopy Consultancy Services (AMCS)
  • AMCS will provide technical, marketing and sales services to OptiScan in the U.S. and Canada
  • This means OptiScan has ended its distribution agreement with Scinitca Instrumentation although it continues to explore potential opportunities to work with Scinitca
  • The altering of the agreements follows the company’s recent engagement with a consultant, Dr Joesph Jiafu
  • On the market close, Optiscan is down 6.67 per cent and last traded for 5.6 cents

Microscopic imaging company OptiScan Imaging (OIL) has changed its North American distribution arrangements.

The company has entered into an agreement with Advanced Microscopy Consultancy Services (AMCS) to provide technical, marketing and sales services to OptiScan in the U.S. and Canada.

AMCS provides significant pre-clinical microscopy and imaging services and has multiple contacts in the research community.

This means OptiScan has ended its distribution agreement with Scinitca Instrumentation although it continues to explore potential opportunities to work with Scinitca.

The altering of the agreements follows the company’s recent engagement with a consultant, Dr Joesph Jiafu. Joesph was hired to assist OptiScan to establish distribution arrangements in Japan, Korea, Singapore and other Asia Pacific countries (excluding China).

“We are excited to build upon our recent sales in the China market by adding highly qualified and experienced people to develop sales and distribution
opportunities in North America and Asia,” Executive Chair and CEO Darren Lurie said.

‘In addition, we have been able to enhance the technical, microscopy and pre-clinical application knowledge within the Company which will benefit us in all market,” he added.

On the market close, Optiscan is down 6.67 per cent and last traded for 5.6 cents

oil by the numbers
More From The Market Online

LTR Pharma’s SPONTAN investigation in pulmonary arterial hypertension approved

LTR Pharma has received approval for an investigator-initiated clinical study evaluating SPONTAN in patients with newly…

Pro Medicus signs $43M, seven-year contract with Virtua Health in US

Pro Medicus' wholly-owned US subsidiary, Visage Imaging, has signed a seven-year, $43 million contract with Virtua…

Recce welcomes positive phase 3 clinical trial data for topical gel for diabetic foot ulcer infections

Recce Pharmaceuticals has reported a review of blinded data of its current phase 3 trial has…
Blood sample blood test blood concept

Newest ASX listee Identifai Genetics up +20% on IPO day eyeing prenatal screening disruption in the USA

The newest company to hit the ASX, Identifai Genetics (ASX:ID1), has seen its shares jump +20% on some...